Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides

被引:22
作者
El Solh, N [1 ]
Davi, M
Morvan, A
Damon, HA
Marty, N
机构
[1] Inst Pasteur, Unite Staphylocoques, F-75724 Paris, France
[2] Inst Veille Sanit, Dept Malad Infect, F-94415 St Maurice, France
[3] CHU Rangueil, Lab Bacteriol Virol Hyg, F-31403 Toulouse, France
关键词
MRSA; S; aureus; teicoplanin; vancomycin;
D O I
10.1093/jac/dkg400
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
According to the French Society of Microbiology, Staphylococcus aureus isolates are suspected to have decreased susceptibility to glycopeptide(s) when at least one colony is able to grow from an inoculum of 10 muL of 2 McFarland bacterial suspension plated on Mueller-Hinton agar containing 5 mg/L teicoplanin and incubated for 48 h at 35-37degreesC. We analysed 89 methicillin-resistant S. aureus isolates (MRSA), collected in 2000-2001 from 24 hospitals located in 18 French cities, which were able to grow on this selective medium. These isolates were distributed into six groups on the basis of their glycopeptide resistance phenotypes: (A) glycopeptide susceptible (GSSA, 21 isolates); (B) heterogeneous teicoplanin intermediately resistant (hetero-TISA, 24 isolates); (C) heterogeneous and intermediately resistant to both glycopeptides, teicoplanin and vancomycin (hetero-GISA, six isolates); (D) heterogeneous vancomycin intermediately resistant/teicoplanin intermediately resistant (hetero-VISA/TISA, 30 isolates); (E) GISA (four isolates); (F) TISA (four isolates). Despite the persistent decrease in gentamicin-resistant MRSA isolates in French hospitals since 1993, their prevalence is very high in groups D, E and F. Moreover, most of the group C, D and E isolates exhibiting decreased susceptibility to both glycopeptides belong to the same major SmaI genotype, which has been detected in Europe since at least 1989.
引用
收藏
页码:691 / 694
页数:4
相关论文
共 10 条
[1]  
AUBRYDAMON H, 2002, HYGIENE S, V10, P324
[2]   Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals [J].
Chesneau, O ;
Morvan, A ;
El Solh, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) :887-890
[3]   Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital:: microbiological and clinical features [J].
Denis, O ;
Nonhoff, C ;
Byl, B ;
Knoop, C ;
Bobin-Dubreux, S ;
Struelens, MJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (03) :383-391
[4]  
Galdbart JO, 2000, J CLIN MICROBIOL, V38, P185
[5]   Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital [J].
Guerin, F ;
Buu-Hoï, A ;
Mainardi, JL ;
Kac, G ;
Colardelle, N ;
Vaupré, S ;
Gutmann, L ;
Podglajen, I .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (08) :2985-2988
[6]   Vancomycin resistance in Staphylococci [J].
Hiramatsu, K .
DRUG RESISTANCE UPDATES, 1998, 1 (02) :135-150
[7]   Contribution of a typing method based on IS256 probing of SmaI-digested cellular DNA to discrimination of European phage type 77 methicillin-resistant Staphylococcus aureus strains [J].
Morvan, A ;
Aubert, S ;
Godard, C ;
ElSolh, N .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (06) :1415-1423
[8]   INTERPRETING CHROMOSOMAL DNA RESTRICTION PATTERNS PRODUCED BY PULSED-FIELD GEL-ELECTROPHORESIS - CRITERIA FOR BACTERIAL STRAIN TYPING [J].
TENOVER, FC ;
ARBEIT, RD ;
GOERING, RV ;
MICKELSEN, PA ;
MURRAY, BE ;
PERSING, DH ;
SWAMINATHAN, B .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (09) :2233-2239
[9]   The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus [J].
Walsh, TR ;
Howe, RA .
ANNUAL REVIEW OF MICROBIOLOGY, 2002, 56 :657-675
[10]  
2002, DIALYSIS TRANSPL SEP, P602